DexCom, Inc. $DXCM Shares Bought by MGO One Seven LLC

MGO One Seven LLC grew its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 73.5% in the fourth quarter, Holdings Channel.com reports. The fund owned 32,614 shares of the medical device company’s stock after purchasing an additional 13,815 shares during the period. MGO One Seven LLC’s holdings in DexCom were worth $2,165,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Trust Co. of Vermont lifted its position in shares of DexCom by 14.8% during the 4th quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock valued at $74,000 after acquiring an additional 145 shares during the period. CVA Family Office LLC lifted its position in shares of DexCom by 48.5% during the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 147 shares during the period. IFP Advisors Inc lifted its position in shares of DexCom by 24.7% during the 3rd quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock valued at $61,000 after acquiring an additional 178 shares during the period. Personal CFO Solutions LLC increased its stake in shares of DexCom by 5.0% during the 3rd quarter. Personal CFO Solutions LLC now owns 3,864 shares of the medical device company’s stock worth $260,000 after purchasing an additional 185 shares in the last quarter. Finally, Inspire Advisors LLC increased its stake in shares of DexCom by 2.5% during the 3rd quarter. Inspire Advisors LLC now owns 7,926 shares of the medical device company’s stock worth $533,000 after purchasing an additional 194 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

DXCM has been the subject of a number of recent research reports. Canaccord Genuity Group set a $100.00 price objective on shares of DexCom and gave the stock a “buy” rating in a research note on Friday, May 1st. Wells Fargo & Company dropped their price objective on shares of DexCom from $93.00 to $85.00 and set an “overweight” rating for the company in a research note on Friday, February 13th. Morgan Stanley reissued an “overweight” rating on shares of DexCom in a research note on Monday, January 12th. Robert W. Baird set a $80.00 price objective on shares of DexCom in a research note on Friday, May 1st. Finally, Weiss Ratings raised shares of DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, March 4th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, DexCom presently has an average rating of “Moderate Buy” and an average price target of $83.50.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $63.04, for a total value of $107,168.00. Following the transaction, the executive vice president owned 111,204 shares in the company, valued at $7,010,300.16. This trade represents a 1.51% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.28% of the stock is currently owned by company insiders.

DexCom Price Performance

DXCM stock opened at $60.61 on Monday. The stock has a market capitalization of $23.39 billion, a P/E ratio of 25.90, a PEG ratio of 1.04 and a beta of 1.40. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95. DexCom, Inc. has a one year low of $54.11 and a one year high of $89.98. The company has a 50 day moving average price of $65.10 and a two-hundred day moving average price of $66.29.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.47 by $0.09. The firm had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. DexCom’s revenue for the quarter was up 15.0% on a year-over-year basis. During the same period in the previous year, the company earned $0.32 EPS. As a group, sell-side analysts expect that DexCom, Inc. will post 2.56 EPS for the current year.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.